FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer...

[cafead]

via Daiichi Sankyo’s long wait for approval of quizartinib just grew a little longer. Having bounced back from a 2019 rejection, the Japanese drugmaker has now learned the FDA needs another three months to review its second attempt to launch a challenger to Astellas and Novartis in a blood cancer market.

article source